Laurus Labs

Indicators

13 bullish · 6 neutral · 2 bearish

Verdict

Laurus Labs drives consistent revenue and margin expansion, supported by focused manufacturing investment and rising R&D spend.

Why

• •Consolidated revenue grows from ₹1,570 Cr to ₹2,026 Cr over five quarters, while net profit margin expands from 10.4% to 18.2%, showing strong operational leverage.
• •Capital expenditure intensity rises to 19% of revenue, with 94% directed toward API and CDMO facilities, signaling a clear strategic shift away from finished-dose manufacturing.
• •Return on capital employed improves to 19.3% and net leverage stabilizes at 1.3x, reflecting better asset utilization and steady debt reduction.
• •Biologics revenue dips to ₹35 Cr and regulatory filings in Canada, EU, and ROW remain flat, indicating a need to monitor pipeline diversification.

Signals